NCT01442831 is a Phase 1 clinical trial of Human ADME in Healthy, sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

Who is sponsoring NCT01442831?

NCT01442831 is sponsored by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA).

What drugs are being tested in NCT01442831?

Interventions in NCT01442831: Human ADME.

Is NCT01442831 still recruiting?

NCT01442831 is currently completed. Last updated 15 November 2019.

Last reviewed 2019-11-15 · How we verify

NCT01442831

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects

Completed Phase 1 Last updated 15 November 2019

What this trial tests

Phase 1 trial testing Human ADME in Healthy in 6 participants. Completed in 22 September 2010.

Timeline

9 September 2010

Primary endpoint
22 September 2010

22 September 2010

Quick facts

Lead sponsor	Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	9 September 2010
Primary completion	22 September 2010
Estimated completion	22 September 2010
Sites	1 location across United States

Drugs / interventions tested

Human ADME — full drug profile →

Conditions studied

Healthy — all drugs for Healthy →

Sponsor

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) — full company profile →

Who can join

Adults 18 to 50, male only, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to describe the single dose pharmacokinetics of total radioactivity in plasma and whole blood following PO administration of \[14C\] TR-701 in healthy adult male subjects.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Revolutionizing tuberculosis treatment: Breakthroughs, challenges, and hope on the horizon.
Kufa M, Finger V, Kovar O, Soukup O, et al · · 2025 · cited 6× · PMID 40370552 · DOI 10.1016/j.apsb.2025.01.023

Verify or expand the search:

Other recruiting trials for Healthy

Currently open trials in the same condition.

NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting

Other Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) trials

Trials by the same sponsor.

NCT01623401 — A Phase 1, Open-Label, 10 Day Safety Study · Phase 1 · completed
NCT01577459 — A Phase 1 Crossover Study of Blood Pressure and Heart Rate Response · Phase 1 · completed
NCT01519778 — A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study · Phase 2 · completed
NCT01496677 — Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects · Phase 1 · completed
NCT01461460 — A Thorough QT Study of TR-701free Acid (FA) in Healthy Subjects · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01442831 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Last refreshed: 15 November 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01442831.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing